Pal-AHK vs MK-677 (Ibutamoren)
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Pal-AHKGrowth Hormone Peptides
MK-677 (Ibutamoren)- Summary
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- Half-Life
- Extended (lipid depot effect in stratum corneum)
- 24 hours
- Admin Route
- Topical
- Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.05% in formulation
- 10–25 mg
- Frequency
- Once or twice daily
- Once daily
- Key Benefits
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Side Effects
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Stacks With
- —
- —